 |
| ||||||||||||||
 |
||||||||||||||
|
|
 |
| We are engaged in the identification and development of selective PDE inhibitors for novel therapeutic applications. Our current research includes the investigation of inhibitors with the potential for use in the treatment of tropical diseases. We also provide non-clinical support for OPC PDE inhibitors that are being assessed for, or that are currently in, clinical use as therapeutic agents. |
| * OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989 |